Bisphosphonate‐related osteonecrosis of the jaw and its associated risk factors: A belgian case series
Open Access
- 26 January 2009
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 119 (2), 323-329
- https://doi.org/10.1002/lary.20076
Abstract
Objectives: Bisphosphonate-related osteonecrosis of the jaw (BROJ) is a serious oral complication of bisphosphonate (BP) treatment involving the exposure of necrotic maxillary or mandibular bone. Our purpose is to describe the clinical presentation of 34 cases of BROJ and to identify potential risk factors. Study Design: A retrospective study was performed in four Belgian institutions. Methods: Complete medical histories were recorded and analyzed. These data include age, gender, initial disease requiring BP, type and duration of BP treatment, symptomatology and location of BROJ, prior dental procedures, treatment of the BROJ and treatment outcome, and radiographic, histological, and microbiological data. Results: Bisphosphonates (BP) were used in the management of disseminated cancers in 30 patients (88.5% of total studied), while four patients received BP due to osteoporosis (11.5%). The most frequently used BP was zoledronic acid in 29 patients (83%). Microbiological data obtained in 25 patients demonstrated that 72% of these patients were infected or colonized by an actinomyces. Eight of the 14 patients (57%) who received only medical treatment were cured. Of the 20 patients who underwent surgical treatments, only four were completely cured (20%). BROJ lesions smaller than 1 cm are associated with better prognosis in terms of treatment outcomes (P = .0009). Local treatments combined with long-term antibiotics are also correlated with better prognosis (P = .02). Conclusions: Lesions smaller than 1 cm and lesions that were subject to medical treatments are associated with a better outcome. Surgical treatments appear to be non-beneficial for BROJ. Laryngoscope, 119:323–329, 2009Keywords
This publication has 26 references indexed in Scilit:
- Bisphosphonate-related osteonecrosis of the jaws: a comprehensive reviewJournal of Oral Pathology & Medicine, 2007
- American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2007
- Dental management of patients receiving oral bisphosphonate therapyThe Journal of the American Dental Association, 2006
- Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and TreatmentJournal of Oral and Maxillofacial Surgery, 2005
- Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the 21st Century?Journal of Oral and Maxillofacial Surgery, 2005
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumorsSeminars in Oncology, 2003
- Bisphosphonates in the Treatment of Malignant Bone DiseaseAnnual Review of Medicine, 1999
- Bisphosphonates: Mechanisms of Action and Clinical Use in Osteoporosis - An UpdateHormone and Metabolic Research, 1997